Mecasermin rinfabate

Plumbing Industry Has a Role to Play in Contributing to a Responsible and Sustainable Future

Retrieved on: 
Thursday, June 9, 2022
PIPA, Perception, PVC, Queensland Government Printing Office, Maintenance, Construction, GLOBE, Industry, Mecasermin rinfabate, Education, Plumbing, Recycling

According to the leading plumber Port Stephens wide, The Plumbing Life Saver, the scheme highlights the need to educate and change behaviours across the industry.

Key Points: 
  • According to the leading plumber Port Stephens wide, The Plumbing Life Saver, the scheme highlights the need to educate and change behaviours across the industry.
  • The scheme was developed to help industry understand the volume of available PVC off-cuts and fittings from construction sites.
  • The Plumbing Life Saver offers a one-stop solution for affordable 24/7 plumbing services including installation and maintenance of hot water Port Stephens wide.
  • Providing a convenient, reliable and prompt service, for any plumbing issues including fixing blocked drains Port Stephens wide, contact The Plumbing Life Saver .

MediciNova Receives a Notice of Intention to Grant for a New Patent Covering the Combination of MN-166 (ibudilast) and Riluzole for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Europe

Retrieved on: 
Thursday, May 6, 2021
Branches of biology, Neuroscience, Nervous system, Rare diseases, Motor neuron diseases, Neurological disorders, Amyotrophic lateral sclerosis, Nerve, Neurodegeneration, Sclerosis, Mecasermin rinfabate

Previously, similar patents were granted in the U.S. and Japan based on data from our first clinical trial in ALS patents.

Key Points: 
  • Previously, similar patents were granted in the U.S. and Japan based on data from our first clinical trial in ALS patents.
  • "\nAmyotrophic lateral sclerosis (ALS), also known as\xc2\xa0Lou Gehrig\'s\xc2\xa0disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord.
  • As a result, ALS affects voluntary movement and patients in the later stages of the disease may become completely paralyzed.
  • Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof.

Orphazyme announces topline results from pivotal trial of arimoclomol for Inclusion Body Myositis (IBM)

Retrieved on: 
Monday, March 29, 2021
Branches of biology, Neurological disorders, Biology, Rare diseases, Neuroscience, Amyotrophic lateral sclerosis, Inclusion bodies, Myositis, Neurodegeneration, Mecasermin rinfabate

The primary goal was to evaluate the treatment effect on disease progression as measured by the inclusion body myositis functional rating scale (IBMFRS).

Key Points: 
  • The primary goal was to evaluate the treatment effect on disease progression as measured by the inclusion body myositis functional rating scale (IBMFRS).
  • Participants were randomized (1:1 ratio) to receive either arimoclomol citrate (400 mg three times daily) or placebo for up to 20 months.
  • We recognize these data are disappointing for patients and families who continue to eagerly await a promising option for IBM.
  • Orphazyme expects data from a pivotal Phase 3 trial of arimoclomol in Amyotrophic Lateral Sclerosis (ALS), a neurodegenerative disease, this spring.

BrainStorm to present NurOwn® Phase 3 Clinical Trial Results at 31st International Symposium on ALS/MND

Retrieved on: 
Monday, November 23, 2020
Health sciences, Clinical research, Health, Medical research, Design of experiments, Pharmaceutical industry, Drug discovery, Clinical trials, Placebo-controlled study, Mecasermin rinfabate, Ozanezumab

In addition, Brainstorm will present the clinical experience with NurOwn outpatient administration during the phase 3 clinical trial in the poster session.

Key Points: 
  • In addition, Brainstorm will present the clinical experience with NurOwn outpatient administration during the phase 3 clinical trial in the poster session.
  • "We are encouraged by the results of the phase 3 pivotal trial of NurOwn in ALS and are privileged to make these important scientific presentations to the 31st International Symposium on ALS/MND."
  • We believe that there are important insights from our clinical trial and that NurOwn could potentially benefit ALS patients."
  • The Phase 3 NurOwn trial was a multi-center, placebo-controlled, randomized, double-blind trial designed to evaluate the safety and efficacy of NurOwn in 189 ALS patients.

BrainStorm Announces Topline Results from NurOwn® Phase 3 ALS Study

Retrieved on: 
Tuesday, November 17, 2020
Health sciences, Clinical research, Health, Design of experiments, Placebo-controlled study, Clinical trial, Placebo, Ozanezumab, Mecasermin rinfabate

Results from the trial showed that NurOwn was generally well tolerated in this population of rapidly progressing ALS patients.

Key Points: 
  • Results from the trial showed that NurOwn was generally well tolerated in this population of rapidly progressing ALS patients.
  • Therefore, the trial met the expected 35% NurOwn treatment group efficacy response assumption, however the high placebo response exceeded placebo responses observed in contemporary ALS trials.
  • "This clinical trial included a more severely affected ALS population compared to other recent ALS clinical trials.
  • The Phase 3 NurOwn trial was a multi-center, placebo-controlled, randomized, double-blind trialdesigned to evaluate the safety and efficacy of NurOwn in 189 ALS patients.

Alexion Announces Planned Initiation of Pivotal Phase 3 Study of ULTOMIRIS® (ravulizumab) in ALS

Retrieved on: 
Tuesday, January 14, 2020
Biotechnology, General Health, Health, Pharmaceutical, Clinical trials, Health, Life sciences, Articles, Alexion Pharmaceuticals, Investigational New Drug, Amyotrophic lateral sclerosis, Mecasermin rinfabate

Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the planned initiation of a pivotal Phase 3 study of ULTOMIRIS (ravulizumab) in amyotrophic lateral sclerosis (ALS).

Key Points: 
  • Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the planned initiation of a pivotal Phase 3 study of ULTOMIRIS (ravulizumab) in amyotrophic lateral sclerosis (ALS).
  • Alexion submitted an investigational new drug application (IND) for ULTOMIRIS in ALS to the FDA in the fourth quarter of 2019 and plans to initiate the Phase 3 study this quarter.
  • The Phase 3 CHAMPION-ALS trial is a randomized, double-blind, placebo-controlled multicenter global study designed to evaluate the efficacy and safety of ULTOMIRIS across a broad ALS population.
  • After 50 weeks, all patients will receive ULTOMIRIS in a 2-year open-label extension phase of the study.

MediciNova Receives Notice of Allowance for New Patent Covering MN-166 (ibudilast) for the Treatment of Amyotrophic Lateral Sclerosis (ALS) in Canada

Retrieved on: 
Monday, October 28, 2019
Neurological disorders, Neurodegenerative disorders, Organ systems, Rare diseases, Motor neuron diseases, Amyotrophic lateral sclerosis, RTT, Orphan drugs, Mecasermin rinfabate, Progressive muscular atrophy

Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2028.

Key Points: 
  • Once issued, the patent maturing from this allowed patent application is expected to expire no earlier than July 2028.
  • Previously, the U.S. FDAgranted both orphan-drug designation and fast-track designation and the European Commission granted Orphan Medicinal Product Designation to MN-166 for the treatment of ALS."
  • Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord.
  • As a result, ALS affects voluntary movement and patients in the later stages of the disease may become completely paralyzed.

Amylyx Pharmaceuticals Announces Last Patient Completes Last Study Visit in CENTAUR Phase 2 Study of AMX0035 in ALS

Retrieved on: 
Friday, October 4, 2019
Research, Clinical trials, Other Health, Pharmaceutical, Health, General Health, Science, Organ systems, Neurological disorders, Branches of biology, Rare diseases, Amyotrophic lateral sclerosis, RTT, Combination drugs, Neurodegeneration, Draft:BrainStorm Cell Therapeutics, Mecasermin rinfabate, AMX0035, Amylyx Pharmaceuticals

ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord.

Key Points: 
  • ALS is a progressive neurodegenerative disease that affects nerve cells in the brain and the spinal cord.
  • CENTAUR is a 24-week, randomized, double-blind, placebo-controlled Phase II clinical trial in people with ALS.
  • In 2017, AMX0035 was granted orphan drug status by the U.S. Food and Drug Administration (FDA) as a potential medicine for ALS.
  • Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company developing a novel therapeutic for Amyotrophic Lateral Sclerosis (ALS), Alzheimers disease and other neurodegenerative diseases.

Collaborative Medicinal Development, LLC Reports that Lead Drug Modifies ALS Progression

Retrieved on: 
Monday, January 7, 2019
Health, Nervous system, Biology, Rare diseases, Motor neuron diseases, Amyotrophic lateral sclerosis, RTT, Neurodegeneration, Clinical trial, Mecasermin rinfabate, Ozanezumab

At lower CuATSM dose levels, evaluable patients showed expected decreases in ALSFRS-R score and FVC over 24 weeks, providing a dramatic dose-response effect previously observed in ALS mouse models.

Key Points: 
  • At lower CuATSM dose levels, evaluable patients showed expected decreases in ALSFRS-R score and FVC over 24 weeks, providing a dramatic dose-response effect previously observed in ALS mouse models.
  • CMD plans to initiate a randomized, placebo-controlled study of CuATSM in ALS to confirm the promising results seen in the open-label phase 1 study.
  • The Company's lead drug, CuATSM, was licensed from the University of Melbourne and entered clinical trials in ALS and Parkinson's disease in 2017 at leading clinical centers in Australia.
  • ALS is a progressive and fatal neurodegenerative disease characterized by muscle weakness resulting from degeneration of motor neurons.